Results 131 to 140 of about 5,328 (181)

Advances in Tissue-Agnostic Targeting in Cancer Therapeutics: Current Approvals, Challenges, and Future Directions. [PDF]

Oncol Res
Rubinstein M, Hong ML, Nanda RK, Jones DT, Aboaid H, Myat YM, Thein KZ.   +6 more
europepmc   +1 more source

TRK Inhibition:A New Tumor-Agnostic Treatment Strategy [PDF]

, 2018
Kummar, Shivaani, Lassen, Ulrik N
core   +1 more source

Tropomyosin 3 Gene Fusions in Cancers: From Mechanisms to Treatments-A Comprehensive Review. [PDF]

Cancer Med
Chen A, Li S, Guo C, Gu C, Gui J, Deng Y, Feng X, Mi Y.   +7 more
europepmc   +1 more source

Case Report: Malignant peritoneal mesothelioma with TFG-ROS1 fusion responds to crizotinib. [PDF]

Front Oncol
Ye W, Li P, Fu C, Zhou T.
europepmc   +1 more source

Visceral crisis in a patient with non-small cell lung cancer and <i>ROS1::SDC4</i> fusion: intrinsic resistance to entrectinib via L2026M mutation-a case report. [PDF]

Transl Lung Cancer Res
Avila Rodriguez V, Wagner-Gutiérrez N, Zuluaga León JA, Rojas L, Viola L, Martínez Jaramillo SI, Carvajal Fierro CA, Ruiz-Patiño A, Arrieta O, Corrales L, Martin C, Cardona AF.   +11 more
europepmc   +1 more source

Targeting proteostasis in multiple myeloma through inhibition of LTK. [PDF]

Leukemia
Våtsveen TK, Giliberto M, Bjornsdottir V, Centonze F, Besse A, Frey Y, Skånland SS, Tveita A, Alirezaylavasani A, Imbery JF, Misund K, Reiterer V, Zahoor M, Driessen C, Besse L, Tasken K, Schjesvold FH, Farhan H, Munthe LA.   +18 more
europepmc   +1 more source

Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations. [PDF]

Mol Cancer Ther
Tangpeerachaikul A, Mente S, Magrino J, Gu F, Horan JC, Pelish HE.   +5 more
europepmc   +1 more source

Coverage with evidence development for medicines with insufficient evidence of clinical benefit: experience from the Netherlands. [PDF]

Int J Technol Assess Health Care
Versteeg JW, Stam N, Mantel-Teeuwisse AK, Timmers L, Goettsch W, Leopold C.   +5 more
europepmc   +1 more source

Neurotrophin NGF/TrkA and BDNF/TrkB signaling orchestrates the immune microenvironment in osteosarcoma. [PDF]

Front Immunol
Liu H, Wang G, Wang C, Hou D, Li S, Fan Y, Liu B.   +6 more
europepmc   +1 more source

Addressing challenges with Matching-Adjusted Indirect Comparisons to demonstrate the comparative effectiveness of entrectinib in metastatic ROS-1 positive Non-Small Cell Lung Cancer. [PDF]

BMC Med Res Methodol
Esnault C, Baschet L, Barbet V, Chenuc G, Pérol M, Thokagevistk K, Pau D, Monnereau M, Bosquet L, Filleron T.   +9 more
europepmc   +1 more source